CASI Pharmaceuticals, Inc.·4

Nov 14, 5:14 PM ET

CASI Pharmaceuticals, Inc. 4

4 · CASI Pharmaceuticals, Inc. · Filed Nov 14, 2014

Insider Transaction Report

Form 4
Period: 2014-09-17
Ren Ken Keyong
Chief Executive Officer
Transactions
  • Award

    Stock Options(Right to Buy)

    2014-04-03+100,000100,000 total
    Exercise: $1.84Exp: 2024-04-03Common Stock (100,000 underlying)
Footnotes (1)
  • [F1]The stock options vested as a result of the reported license transaction with Spectrum Pharmaceuticals, Inc. on September 17, 2014.

Documents

1 file
  • 4
    v394481_4.xmlPrimary

    OWNERSHIP DOCUMENT